Tevogen Bio Holdings Inc. (NASDAQ:TVGN – Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 648,700 shares, a growth of 28.6% from the July 31st total of 504,300 shares. Based on an average daily trading volume, of 283,100 shares, the short-interest ratio is currently 2.3 days. Approximately 3.4% of the company’s stock are short sold.
Analyst Ratings Changes
Separately, Fundamental Research set a $4.20 price objective on shares of Tevogen Bio and gave the company a “buy” rating in a research report on Friday, June 28th.
View Our Latest Research Report on TVGN
Institutional Inflows and Outflows
Tevogen Bio Price Performance
TVGN opened at $0.52 on Friday. The business’s 50-day moving average price is $0.66. Tevogen Bio has a fifty-two week low of $0.42 and a fifty-two week high of $21.09.
Tevogen Bio Company Profile
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Featured Stories
- Five stocks we like better than Tevogen Bio
- Where Do I Find 52-Week Highs and Lows?
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- What is Forex and How Does it Work?
- Why Dell Can Continue Winning in AI and Beyond
- 3 Best Fintech Stocks for a Portfolio Boost
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.